MAC Clinical Research are currently conducting a trial to test a potential new treatment for ulcerative colitis (UC).
Improving quality of life
Register Your Interest
What Happens Next?
About this Ulcerative Colitis Clinical Trial
Ulcerative Colitis (UC) is a chronic inflammatory disease of the rectal & colonic mucosa which is characterised by periods of remission and relapse, or ‘flare-ups’. Autoimmune and inflammatory diseases such as UC can happen when a person’s immune system becomes unbalanced. The study medicine, PT101, has been developed as a variation of a protein in our bodies known as interleukin-2 (IL-2). In previous studies PT101 has been shown to increase a type of immune cell in the body called regulatory T cells (Tregs), which are believed to bring balance back to the immune system and help reduce acute inflammation, a cause of UC flare-ups.
– Age 18 – 80
– Diagnosis of ulcerative colitis for at least the past 3 months
– BMI of 18 – 35; minimum weight of 50kg
– Active ulcerative colitis
– Currently experiencing increased stool frequency
– Currently passing at least some blood during bowel movements